Skip to main content
. 2023 Aug 14;9(4):00181-2023. doi: 10.1183/23120541.00181-2023

TABLE 2.

Adverse events

Prone positioning group Control group
Subjects, n 29 32
Clinically relevant adverse events
 Thromboembolic event 2 (6.9) 3 (9.4)
 Gastrointestinal bleeding 0 1 (3.1)
 Cardiovascular events 2 (6.9) 1 (3.1)
 Infection 3 (10.3) 4 (12.5)
Grade ≥3 adverse events # 4 (13.8) 6 (18.7)

Data are presented as n (%), unless otherwise indicated. #: severity scale: 1=mild, 2=moderate, 3=serious, 4=life-threatening, 5=fatal.